Safety of Lipid-Lowering Therapy with Statins according to a Regional Pharmacovigilance Centre

Scientific relevance. Since statins are widely used to prevent cardiovascular diseases, the control of statin-related complications is essential from both medical and social perspectives.
Aim. The study aimed to analyse unsolicited reports on adverse drug reactions (ADRs) to control the safety of statin therapy.
Materials and methods. The study analysed information on ADRs observed during statin treatment from the reporting forms submitted by medical organisations in Irkutsk to the database of the Regional Centre for Drug Safety Monitoring of the Irkutsk Region in 2011–2022. The causal relationship between ADRs and statin therapy was assessed using the Naranjo scale.
Results. The database contained 1068 ADR reporting forms; 12 (1.1%) were spontaneous reports of statin-related complications, including 4 cases (33.4%) of myalgia, 7 cases (58.3%) of myalgia with moderately elevated transaminase levels (3–5 times the upper limit of normal), and 1 case of rhabdomyolysis that required statin discontinuation. In all cases, a reduction in the statin dose resulted in a regression in the clinical symptoms of ADRs. Most ADRs were observed in women with comorbidities (diabetes mellitus, obesity, and hypothyroidism), but the small sample size prevented the authors from testing the identified differences for statistical significance.
Conclusions. According to the study results, statins have a reliable safety profile. Adequate and patient-specific selection of statin doses and ADR prevention are important responsibilities of clinical practitioners.

1. Kukharchuk VV, Ezhov MV, Sergienko IV, Arabidze GG, Bubnova MG, Balakhonova TV, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Journal of Atherosclerosis and Dyslipidemias. 2020;(1):7–40 (In Russ.). https://doi.org/10.34687/2219-8202.JAD.2020.01.0002

2. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):CD004816. https://doi.org/10.1002/14651858.CD004816.pub5

3. Noyes AM, Thompson PD. The effects of statins on exercise and physical activity. J Clin Lipidol. 2017;11(5):1134–44. https://doi.org/10.1016/j.jacl.2017.07.003

4. Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633–72. https://doi.org/10.1152/physrev.00002.2019

5. Sychev DA, Ostroumova OD, Pereverzev AP, eds. Drug-induced diseases. V. I. Moscow: Prometheus; 2022 (In Russ.).

6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154

7. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043

8. Dyadyk AI, Kugler TE, Suliman YV, Zborovskyy SR, Zdykhovskaya II. Statin adverse effects: mechanisms, diagnosis, prevention and management. The Russian Archives of Internal Medicine. 2018;8(4):266–76 (In Russ.). https://doi.org/10.20514/2226-6704-2018-8-4-266-276

9. Soboleva NI. Adverse effects of statin therapy in older patients. Clinical Gerontology. 2020;(5–6):34– 8 (In Russ.). EDN: EDQXAB

10. Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96(12):4211–8. https://doi.org/10.1161/01.cir.96.12.4211

11. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22. https://doi.org/10.1016/S0140-6736(02)09327-3

12. Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev. 2020;100(2):633–72. https://doi.org/10.1152/physrev.00002.2019

13. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455

14. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273–93. https://doi.org/10.1146/annurev-pharmtox-011613-140025

15. Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T. Are PCSK9 inhibitors cost effective? Pharmacoeconomics. 2018;36(9):1031–41. https://doi.org/10.1007/s40273-018-0671-0